Kim Seung-Jae, Chen Zhenlong, Chamberlain Nathan D, Essani Abdul B, Volin Michael V, Amin M Asif, Volkov Suncica, Gravallese Ellen M, Arami Shiva, Swedler William, Lane Nancy E, Mehta Anjali, Sweiss Nadera, Shahrara Shiva
Division of Rheumatology, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612;
Department of Microbiology and Immunology, Midwestern University, Chicago College of Osteopathic Medicine, Downers Grove, IL 60515;
J Immunol. 2014 Oct 15;193(8):3902-13. doi: 10.4049/jimmunol.1302998. Epub 2014 Sep 8.
Our aim was to examine the impact of TLR5 ligation in rheumatoid arthritis (RA) and experimental arthritis pathology. Studies were conducted to investigate the role of TLR5 ligation on RA and mouse myeloid cell chemotaxis or osteoclast formation, and in addition, to uncover the significance of TNF-α function in TLR5-mediated pathogenesis. Next, the in vivo mechanism of action was determined in collagen-induced arthritis (CIA) and local joint TLR5 ligation models. Last, to evaluate the importance of TLR5 function in RA, we used anti-TLR5 Ab therapy in CIA mice. We show that TLR5 agonist, flagellin, can promote monocyte infiltration and osteoclast maturation directly through myeloid TLR5 ligation and indirectly via TNF-α production from RA and mouse cells. These two identified TLR5 functions are potentiated by TNF-α, because inhibition of both pathways can more strongly impair RA synovial fluid-driven monocyte migration and osteoclast differentiation compared with each factor alone. In preclinical studies, flagellin postonset treatment in CIA and local TLR5 ligation in vivo provoke homing and osteoclastic development of myeloid cells, which are associated with the TNF-α cascade. Conversely, CIA joint inflammation and bone erosion are alleviated when TLR5 function is blocked. We found that TLR5 and TNF-α pathways are interconnected, because TNF-α is produced by TLR5 ligation in RA myeloid cells, and anti-TNF-α therapy can markedly suppress TLR5 expression in RA monocytes. Our novel findings demonstrate that a direct and an indirect mechanism are involved in TLR5-driven RA inflammation and bone destruction.
我们的目的是研究Toll样受体5(TLR5)激活在类风湿关节炎(RA)及实验性关节炎病理过程中的影响。开展了多项研究,以探究TLR5激活在RA以及小鼠髓样细胞趋化性或破骨细胞形成中的作用,此外,还旨在揭示肿瘤坏死因子-α(TNF-α)功能在TLR5介导的发病机制中的意义。接下来,在胶原诱导的关节炎(CIA)和局部关节TLR5激活模型中确定了体内作用机制。最后,为评估TLR5功能在RA中的重要性,我们在CIA小鼠中使用了抗TLR5抗体疗法。我们发现,TLR5激动剂鞭毛蛋白可通过髓样TLR5激活直接促进单核细胞浸润和破骨细胞成熟,还可通过RA细胞和小鼠细胞产生TNF-α间接促进上述过程。TNF-α可增强这两种已确定的TLR5功能,因为与单独抑制每种因素相比,同时抑制这两条途径能更强烈地削弱RA滑液驱动的单核细胞迁移和破骨细胞分化。在临床前研究中,CIA发病后给予鞭毛蛋白治疗以及体内局部TLR5激活可引发髓样细胞归巢和破骨细胞发育,这与TNF-α级联反应有关。相反,当TLR5功能被阻断时,CIA关节炎症和骨侵蚀会减轻。我们发现TLR5和TNF-α途径相互关联,因为RA髓样细胞中TLR5激活可产生TNF-α,而抗TNF-α疗法可显著抑制RA单核细胞中TLR5的表达。我们的新发现表明,TLR5驱动的RA炎症和骨破坏涉及直接和间接两种机制。